Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

ACS Central Science

Volumn 6, Issue 3, 2020, Pages 315-331

  Liu, Cynthia ^a   Zhou, Qiongqiong ^a   Li, Yingzhu ^a   Garner, Linda V ^a   Watkins, Steve P ^a   Carter, Linda J ^a   Smoot, Jeffrey ^a   Gregg, Anne C ^a   Daniels, Angela D ^a   Jervey, Susan ^a   Albaiu, Dana ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENE EXPRESSION; NUCLEIC ACIDS; PATENTS AND INVENTIONS; VACCINES; VIRUSES;

PATENT ANALYSIS; PATHOPHYSIOLOGY; POTENTIAL THREATS; RESEARCH AND DEVELOPMENT; SCIENTIFIC INFORMATION; SMALL MOLECULES; THERAPEUTIC AGENTS; THERAPEUTIC ANTIBODIES;

DISEASES;

EID: 85082319526     PISSN: 23747943     EISSN: 23747951     Source Type: Journal    
DOI: 10.1021/acscentsci.0c00272     Document Type: Article

References (57)

1. Gorbalenya, A. E. et al. The species severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 2020, DOI:10.1038/s41564-020-0695-z.
2. Kupferschmidt, K.; Cohen, J. Will novel virus go pandemic or be contained? Science 2020, 367 (6478), 610-611.
3. Coronavirus Disease (COVID-2019) Situation Reports 1-45; World Health Organization, 2020.https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
4. Coronavirus is now expected to curb global economic growth by 0.3% in 2020. https://www.forbes.com/sites/sergeiklebnikov/2020/02/11/coronavirus-is-now-expected-to-curb-global-economic-growthby-03-in-2020/#5de149ad16da.
5. Anthony, S. J.; Johnson, C. K.; Greig, D. J.; Kramer, S.; Che, X.; Wells, H.; Hicks, A. L.; Joly, D. O.; Wolfe, N. D.; Daszak, P.; Karesh, W.; Lipkin, W. I.; Morse, S. S.; Mazet, J. A. K.; Goldstein, T. Global patterns in coronavirus diversity. Virus Evol 2017, 3 (1), vex012.
6. Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A. C.K.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G. F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016, 24 (6), 490-502.
7. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G. F.; Tan, W. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727-733.
8. Tang, B.; Bragazzi, N. L.; Li, Q.; Tang, S.; Xiao, Y.; Wu, J. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infect Dis Model 2020, 5, 248-255.
9. Du, L.; He, Y.; Zhou, Y.; Liu, S.; Zheng, B.-J.; Jiang, S. The spike protein of SARS-CoV-A target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009, 7 (3), 226-236.
10. Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S. Cryo-EM structure of the 2019-nCoV Spike in the prefusion conformation. Science 2020, eabb2507.
11. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Kruger, N.; Herrler, T.; Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; Muller, M. A.; Drosten, C.; Pohlmann, S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, DOI:10.1016/j.cell.2020.02.052. [Epub ahead of print].
12. Gorbalenya, A. E.; Snijder, E. J.; Ziebuhr, J. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 2000, 81 (4), 853-879.
13. Baez-Santos, Y. M.; St. John, S. E.; Mesecar, A. D. The SARScoronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015, 115, 21-38.
14. Lee, T.-W.; Cherney, M. M.; Huitema, C.; Liu, J.; James, K. E.; Powers, J. C.; Eltis, L. D.; James, M. N.G. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substratelike aza-peptide epoxide. J. Mol. Biol. 2005, 353 (5), 1137-1151.
15. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J; Wang, D.; Xu, W.; Holmes, E. C; Gao, G. F; Wu, G.; Chen, W.; Shi, W.; Tan, W. Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020, 395, 565-574.
16. Morse, J. S.; et al. Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 2020, 21 (5), 730-738.
17. Chan, J. F.-W.; Kok, K.-H.; Zhu, Z.; Chu, H.; To, K. K.-W.; Yuan, S.; Yuen, K.-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes Infect. 2020, 9, 221-236.
18. Dong, N., et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China, bioRxiv 2020, DOI:10.1101/2020.01.20.913368.
19. Sheahan, T. P.; Sims, A. C.; Leist, S. R.; Schafer, A.; Won, J.; Brown, A. J.; Montgomery, S. A.; Hogg, A.; Babusis, D.; Clarke, M. O.; Spahn, J. E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J. Y.; Cihlar, T.; Jordan, R.; Denison, M. R.; Baric, R. S. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Nat. Commun. 2020, Ahead of Print. DOI:10.1038/s41467-019-13940-6.
20. Kadam, R. U.; Wilson, I. A. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc. Natl. Acad. Sci. U. S. A. 2017, 114 (2), 206-214.
21. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). https://www.nature.com/articles/d41573-020-00016-0.
22. The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI). https://clinicaltrials.gov/ct2/show/NCT04252885.
23. Glowacka, I.; Bertram, S.; Herzog, P.; Pfefferle, S.; Steffen, I.; Muench, M. O.; Simmons, G.; Hofmann, H.; Kuri, T.; Weber, F.; Eichler, J.; Drosten, C.; Pohlmann, S. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. Journal of Virology 2010, 84 (2), 1198.
24. Wu, Y.Compensation of ACE2 function for possible clinical management. Virol. Sin. 2020, DOI: 10.1007/s12250-020-00205-6. [Epub ahead of print].
25. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; Breitbart, R. E.; Acton, S. A novel angiotensin-converting enzymerelated carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87 (5), 426.
26. Imai, Y.; Kuba, K.; Rao, S.; Huan, Y.; Guo, F.; Guan, B.; Yang, P.; Sarao, R.; Wada, T.; Leong-Poi, H.; Crackower, M. A.; Fukamizu, A.; Hui, C.-C.; Hein, L.; Uhlig, S.; Slutsky, A. S.; Jiang, C.; Penninger, J. M. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436 (7047), 112-116.
27. Tipnis, S. R.; Hooper, N. M.; Hyde, R.; Karran, E.; Christie, G.; Turner, A. J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 2000, 275 (43), 33238-33243.
28. De Witt, B. J; Garrison, E. A; Champion, H. C; Kadowitz, P. J. L-163, 491 is a partial angiotensin AT (1) receptor agonist in the hindquarters vascular bed of the cat. Eur. J. Pharmacol. 2000, 404 (1-2), 213-219.
29. Guo, D. Old weapon for new enemy: Drug repurposing for treatment of newly emerging viral diseases. Virol. Sin. 2020, DOI:10.1007/s12250-020-00204-7. [Epub ahead of print].
30. Maxmen, A. More than 80 clinical trials launch to test coronavirus treatments. Nature 2020, 578 (7795), 347-348.
31. Arabi, Y. M; Shalhoub, S.; Mandourah, Y.; Al-Hameed, F.; Al-Omari, A.; Al Qasim, E.; Jose, J.; Alraddadi, B.; Almotairi, A.; Al Khatib, K.; Abdulmomen, A.; Qushmaq, I.; Sindi, A. A; Mady, A.; Solaiman, O.; Al-Raddadi, R.; Maghrabi, K.; Ragab, A.; Al Mekhlafi, G. A; Balkhy, H. H; Al Harthy, A.; Kharaba, A.; Gramish, J. A; Al-Aithan, A. M; Al-Dawood, A.; Merson, L.; Hayden, F. G; Fowler, R. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clin. Infect. Dis. 2019, DOI:DOI:10.1093/cid/ciz544. [Epub ahead of print].
32. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020, 30, 269.
33. Kangji Xinguangzhuang Bingdu Feiyan Zhuanli Xinxi Yanbao. https://tech.sina.cn/2020-02-17/detail-iimxxstf2046715.d.html.
34. Warren, T. K.; Wells, J.; Panchal, R. G.; Stuthman, K. S.; Garza, N. L.; Van Tongeren, S. A.; Dong, L.; Retterer, C. J.; Eaton, B. P.; Pegoraro, G.; Honnold, S.; Bantia, S.; Kotian, P.; Chen, X.; Taubenheim, B. R.; Welch, L. S.; Minning, D. M.; Babu, Y. S.; Sheridan, W. P.; Bavari, S. Protection Against Filovirus Diseases by a Novel Broad-Spectrum Nucleoside Analogue BCX4430. Nature 2014, 508 (7496), 402-405.
35. Richardson, P.; Griffin, I.; Tucker, C.; Smith, D.; Oechsle, O.; Phelan, A.; Stebbing, J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020, 395 (10223), e30-e31.
36. Mifsud, E. J.; Hayden, F. G.; Hurt, A. C. Antivirals targeting the polymerase complex of influenza viruses. Antiviral Res. 2019, 169, 104545.
37. Zeldin, R. K. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J. Antimicrob. Chemother. 2003, 53 (1), 4-9.
38. Ortiz-Alcantara, J.; et al. Small molecule inhibitors of the SARSCoV NSP15 endoribonuclease. Virus Adapt. Treat. 2010, 2, 125-133.
39. Zhou, Y.; Vedantham, P.; Lu, K.; Agudelo, J.; Carrion, R.; Nunneley, J. W.; Barnard, D.; Pohlmann, S.; McKerrow, J. H.; Renslo, A. R.; Simmons, G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015, 116, 76-84.
40. Kumar, V.; Shin, J. S.; Shie, J.-J.; Ku, K. B.; Kim, C.; Go, Y. Y.; Huang, K.-F.; Kim, M.; Liang, P.-H. Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017, 141, 101-106.
41. Anand, K. Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs. Science 2003, 300 (5626), 1763-1767.
42. Li, F. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor. Science 2005, 309 (5742), 1864-1868.
43. Bisht, H.; Roberts, A.; Vogel, L.; Subbarao, K.; Moss, B. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein. Virology 2005, 334 (2), 160-165.
44. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. Lancet 2020, 395, 497-506.
45. Yang, Z.-Y.; Huang, Y.; Ganesh, L.; Leung, K.; Kong, W.-P.; Schwartz, O.; Subbarao, K.; Nabel, G. J. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein andenhanced by dendritic cell transfer through DCSIGN. J. Virol. 2004, 78, 5642-5650.
46. Marzi, A.; Gramberg, T.; Simmons, G.; Moller, P.; Rennekamp, A. J.; Krumbiegel, M.; Geier, M.; Eisemann, J.; Turza, N.; Saunier, B.; Steinkasserer, A.; Becker, S.; Bates, P.; Hofmann, H.; Pohlmann, S. DC-SIGN and DCSIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J. Virol 2004, 78, 12090-12095.
47. The overview of Interferon. https://www.cusabio.com/c-20629.html.
48. Zeng, J. Cross Kingdom small RNAs among Animals, Plants and Microbes Cells 2019, 8 (4) 371, DOI:10.3390/cells8040371.
49. Yan, B. microRNAs in Cardiovascular Disease: Small Molecules but Big Roles. Current Topics in Medicinal Chemistry 2019, 19 (21), 1918-1947.
50. Liu, J.; Guo, B. RNA-based therapeutics for colorectal cancer: Updates and future Directions. Pharmacol. Res. 2020, 152, 104550.
51. Buchholz, U. J.; Bukreyev, A.; Yang, L.; Lamirande, E. W.; Murphy, B. R.; Subbarao, K.; Collins, P. L. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (26), 9804-9809.
52. GlaxoSmithKline press release on 2/24/20. https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-researchcollaboration-to-evaluate-coronavirus-covid-19-vaccine-candidatewith-pandemic-adjuvant-system.
53. Generex press release on 2/27/20. https://storage.googleapis.com/wzukusers/user-26831283/documents/5e57ed391b286sVf68Kq/PR-Generex-Coronavirus-Update-2-27-2020.pdf.
54. Novavax press release on 2/26/20. http://ir.novavax.com/news-releases/news-release-details/novavax-advances-developmentnovel-covid-19-vaccine.
55. Moderna press release on 2/24/2020. https://investors.modernatx.com/news-releases/news-release-details/moderna-shipsmrna-vaccine-against-novel-coronavirus-mrna-1273.
56. Modjarrad, K.; Roberts, C. C; Mills, K. T; Castellano, A. R; Paolino, K.; Muthumani, K.; Reuschel, E. L; Robb, M. L; Racine, T.; Oh, M.-d.; Lamarre, C.; Zaidi, F. I; Boyer, J.; Kudchodkar, S. B; Jeong, M.; Darden, J. M; Park, Y. K; Scott, P. T; Remigio, C.; Parikh, A. P; Wise, M. C; Patel, A.; Duperret, E. K; Kim, K. Y; Choi, H.; White, S.; Bagarazzi, M.; May, J. M; Kane, D.; Lee, H.; Kobinger, G.; Michael, N. L; Weiner, D. B; Thomas, S. J; Maslow, J. N Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, doseescalation trial. Lancet Infect. Dis. 2019, 19 (9), 1013-1022.
57. Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800. http://ir.inovio.com/news-and-media/news/pressrelease-details/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx.